Group 1 - SpyGlass Pharma, a biotechnology company focused on chronic eye disease treatments, is in the third phase of clinical trials and has announced its IPO terms, planning to issue 9.4 million shares at a price range of $15-17 per share, aiming to raise $150 million [1] - The fully diluted market capitalization of SpyGlass Pharma is projected to reach $549 million based on the midpoint of the proposed price range [1] - The company's core product is the Bimatoprost Implantable Lens System (BIM-IOL), designed to lower elevated intraocular pressure in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) during routine cataract surgery [1] Group 2 - SpyGlass Pharma was founded in 2019 and plans to list on NASDAQ under the ticker symbol "SGP" [2] - The underwriters for the IPO include Jefferies, Leerink Partners, Citigroup, and Stifel [2]
慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股 拟募资1.5亿美元